ConductScience.org, home

Paper33099752

Ropeginterferon alfa-2b every 2 weeks as a novel pegylated interferon for patients with chronic hepatitis B.

Huang YW and 12 others. Hepatol Int, 2020. Cited by 26 papers, by iCite.

Cite this record

ConductScience Library. Ropeginterferon alfa-2b every 2 weeks as a novel pegylated interferon for patients with chronic hepatitis B. Papers, record 33099752. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33099752

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Ropeginterferon alfa-2b every 2 weeks as a novel pegylated interferon for patients with chronic hepatitis B.
PubMed
Journal
Hepatol Int
PubMed
Year
2020
PubMed
Publication types
Clinical Trial, Phase I, Clinical Trial, Phase II, Journal Article
PubMed
Citations, by iCite
26
iCite
Relative citation ratio, by iCite
1.24
iCite
Revised in PubMed
2021-10-29
PubMed

Authors13

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Huang YWYi-Wen
2Hsu CWChao-Wei
3Lu SNSheng-Nan
4Yu MLMing-Lung
5Su CWChien-Wei
6Su WWWei-Wen
7Chien RNRong-Nan
8Hsu CSChing-Sheng
9Hsu SJShih-Jer
10Lai HCHsueh-Chou
11Qin AAlbert
12Tseng KCKuan-Chiao
13Chen PJPei-Jerhttps://orcid.org/0000-0001-8316-3785

Source PubMed

Download CSV of authors

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Hepatitis B, ChronicMajor topic
Interferon alpha-2Major topic
Antiviral Agents
Hepatitis B Surface Antigens
Hepatitis B e Antigens
Humans
Polyethylene Glycols
Treatment Outcome

Source PubMed

Download CSV of topics

References2

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
118613422Hepatitis B viral genotype in Taiwanese patients with acute hepatitis B.Hepatogastroenterology2008https://conductscience.org/library/papers/18613422PubMed
233383586CD4 Count at Entry into Care and at Antiretroviral Therapy Prescription among Adults with Human Immunodeficiency Virus in the United States, 2005-2018.Clin Infect Dis2021https://conductscience.org/library/papers/33383586PubMed

Download CSV of references

Cited by19

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 26 citations.

PMIDTitleJournalYearIn PapersSource
42865026Safety, Tolerability and Antiviral Activity of GST-HG131 in Chronic Hepatitis B: A Randomized, Double-Blind Phase IIa Study.Liver Int2026https://conductscience.org/library/papers/42865026PubMed
41060606Emerging Significance and Implications of a Durable Complete Molecular Remission in the Treatment of Polycythemia Vera.Curr Hematol Malig Rep2025https://conductscience.org/library/papers/41060606PubMed
40637862A pharmacovigilance study of adverse events associated with polycythemia vera treatments using the FDA Adverse Event Reporting System (FAERS) database.Ann Hematol2025https://conductscience.org/library/papers/40637862PubMed
40335589Investigation into the pharmacodynamics and pharmacokinetics of recombinant human interferon alfa-2b vaginal suppository following process optimization in chinese rhesus macaque.Sci Rep2025https://conductscience.org/library/papers/40335589PubMed
40186764Sequential combination with ropeginterferon alfa-2b and anti-PD-1 treatment as adjuvant therapy in HBV-related HCC: a phase 1 dose escalation trial.Hepatol Int2025https://conductscience.org/library/papers/40186764PubMed
39935794Effect of HBeAg/anti-HBe coexistence on HBeAg seroconversion in treatment-naïve chronic hepatitis B patients with peginterferon-α.Ther Adv Gastroenterol2025https://conductscience.org/library/papers/39935794PubMed
39653378Site-Specific Glyco-Tagging of Native Proteins for the Development of Biologicals.J Am Chem Soc2024https://conductscience.org/library/papers/39653378PubMed
38771550A Phase 3, Randomized, Controlled Trial Evaluating the Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Moderate COVID-19.Infect Dis Ther2024https://conductscience.org/library/papers/38771550PubMed
38644985Effective Management of Polycythemia Vera With Ropeginterferon Alfa-2b Treatment.J Hematol2024https://conductscience.org/library/papers/38644985PubMed
38399475Mouse Type-I Interferon-Mannosylated Albumin Fusion Protein for the Treatment of Chronic Hepatitis.Pharmaceuticals (Basel)2024https://conductscience.org/library/papers/38399475PubMed
38203603
Sequential Therapy with Ropeginterferon Alfa-2b and Anti-Programmed Cell Death 1 Antibody for Inhibiting the Recurrence of Hepatitis B-Related Hepatocellular Carcinoma: From Animal Modeling to Phase I Clinical Results.
Int J Mol Sci2023https://conductscience.org/library/papers/38203603PubMed
38010606Study Protocol of a Randomized Controlled Clinical Trial to Evaluate the Efficacy and Safety of Ropeginterferon Alfa-2b in COVID-19 Patients with Comorbidities.Adv Ther2024https://conductscience.org/library/papers/38010606PubMed
37182173An anti-cancer surveillance by the interplay between interferon-beta and retinoblastoma protein RB1.Front Oncol2023https://conductscience.org/library/papers/37182173PubMed
36776307An alternative dosing strategy for ropeginterferon alfa-2b may help improve outcomes in myeloproliferative neoplasms: An overview of previous and ongoing studies with perspectives on the future.Front Oncol2023https://conductscience.org/library/papers/36776307PubMed
36519386Epidemiology, presentation, and therapeutic approaches for hepatitis D infections.Expert Rev Anti Infect Ther2023https://conductscience.org/library/papers/36519386PubMed
36406648A Phase 3 clinical trial validating the potency and safety of an innovative, extra-long-acting interferon in chronic hepatitis C.JGH Open2022https://conductscience.org/library/papers/36406648PubMed
35746606Novel Pegylated Interferon for the Treatment of Chronic Viral Hepatitis.Viruses2022https://conductscience.org/library/papers/35746606PubMed
34482769Hepatitis D virus (HDV): investigational therapeutic agents in clinical trials.Expert Opin Investig Drugs2022https://conductscience.org/library/papers/34482769PubMed
34386602Ropeginterferon alfa-2b in patients with genotype 1 chronic hepatitis C: Pharmacokinetics, safety, and preliminary efficacy.JGH Open2021https://conductscience.org/library/papers/34386602PubMed

Download CSV of cited by

Genes5

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
ALB213PubTator's text mininghttps://conductscience.org/library/genes/213NCBI Gene
IFNA13439PubTator's text mininghttps://conductscience.org/library/genes/3439NCBI Gene
IFNA23440PubTator's text mininghttps://conductscience.org/library/genes/3440NCBI Gene
KRT88P85348PubTator's text mininghttps://conductscience.org/library/genes/85348NCBI Gene
SLC17A526503PubTator's text mininghttps://conductscience.org/library/genes/26503NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/33099752

GET https://conductscience.org/api/papers/v1/33099752/authors